On Friday, Mirum Pharmaceuticals Inc (NASDAQ: MIRM) opened lower -1.30% from the last session, before settling in for the closing price of $50.70. Price fluctuations for MIRM have ranged from $23.14 to $53.49 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 111.13%. Company’s average yearly earnings per share was noted 59.12% at the time writing. With a float of $38.28 million, this company’s outstanding shares have now reached $47.97 million.
Let’s determine the extent of company efficiency that accounts for 264 employees. In terms of profitability, gross margin is 73.47%, operating margin of -30.44%, and the pretax margin is -31.09%.
Mirum Pharmaceuticals Inc (MIRM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Mirum Pharmaceuticals Inc is 20.21%, while institutional ownership is 93.61%. The most recent insider transaction that took place on Feb 03 ’25, was worth 126,681. In this transaction PRESIDENT AND COO of this company sold 2,627 shares at a rate of $48.22, taking the stock ownership to the 26,961 shares. Before that another transaction happened on Feb 03 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 9,102 for $48.22, making the entire transaction worth $438,921. This insider now owns 115,920 shares in total.
Mirum Pharmaceuticals Inc (MIRM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.12% per share during the next fiscal year.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Trading Performance Indicators
Check out the current performance indicators for Mirum Pharmaceuticals Inc (MIRM). In the past quarter, the stock posted a quick ratio of 3.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.07, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Mirum Pharmaceuticals Inc (MIRM)
Looking closely at Mirum Pharmaceuticals Inc (NASDAQ: MIRM), its last 5-days average volume was 0.34 million, which is a drop from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 46.51%. Additionally, its Average True Range was 1.77.
During the past 100 days, Mirum Pharmaceuticals Inc’s (MIRM) raw stochastic average was set at 78.41%, which indicates a significant increase from 41.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.63% in the past 14 days, which was lower than the 36.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.46, while its 200-day Moving Average is $38.85. However, in the short run, Mirum Pharmaceuticals Inc’s stock first resistance to watch stands at $50.95. Second resistance stands at $51.87. The third major resistance level sits at $52.36. If the price goes on to break the first support level at $49.55, it is likely to go to the next support level at $49.06. Now, if the price goes above the second support level, the third support stands at $48.14.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Key Stats
There are currently 48,005K shares outstanding in the company with a market cap of 2.40 billion. Presently, the company’s annual sales total 186,370 K according to its annual income of -163,420 K. Last quarter, the company’s sales amounted to 90,380 K and its income totaled -14,240 K.
